Gimson A E, Langley P G, Hughes R D, Canalese J, Mellon P J, Williams R, Woods H F, Weston M J
Lancet. 1980 Jan 26;1(8161):173-5. doi: 10.1016/s0140-6736(80)90661-3.
Adverse effects associated with hypotension and the appearance of platelet aggregates in the circulation complicate charcoal haemoperfusion of patients with fulminant hepatic failure. In an attempt to avoid these difficulties the platelet protective effect of prostacyclin (PGI2) given intravenously before and continuously during haemoperfusion was evaluated with an improved charcoal column design. Two of the six patients who underwent haemoperfusion without PGI2 had hypotension, which in one was associated with a striking rise in Swank screen filtration pressure necessitating discontinuation of haemoperfusion after an hour. No platelet losses were observed in the six patients treated with haemoperfusion and PGI2 infusion, and there was significant protection from platelet activation, as assessed by the prevention of release into plasma of the platelet-specific protein beta-thromboglobulin.
暴发性肝衰竭患者进行活性炭血液灌流时，与低血压相关的不良反应以及循环中血小板聚集体的出现使治疗变得复杂。为了避免这些困难，采用改进的活性炭柱设计，评估了在血液灌流前静脉注射并在灌流过程中持续给予前列环素（PGI2）的血小板保护作用。在6例未接受PGI2血液灌流的患者中，有2例出现低血压，其中1例伴有Swank筛滤压显著升高，1小时后不得不停止血液灌流。在接受血液灌流和PGI2输注治疗的6例患者中，未观察到血小板损失，并且通过防止血小板特异性蛋白β-血小板球蛋白释放到血浆中评估，对血小板激活有显著保护作用。
